Principles of Anticancer Drug Development (eBook, PDF)
Redaktion: Garrett-Mayer, Elizabeth
113,95 €
113,95 €
inkl. MwSt.
Sofort per Download lieferbar
57 °P sammeln
113,95 €
Als Download kaufen
113,95 €
inkl. MwSt.
Sofort per Download lieferbar
57 °P sammeln
Jetzt verschenken
Alle Infos zum eBook verschenken
113,95 €
inkl. MwSt.
Sofort per Download lieferbar
Alle Infos zum eBook verschenken
57 °P sammeln
Principles of Anticancer Drug Development (eBook, PDF)
Redaktion: Garrett-Mayer, Elizabeth
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
A practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs.
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 9.94MB
Andere Kunden interessierten sich auch für
- Macromolecular Anticancer Therapeutics (eBook, PDF)209,95 €
- Checkpoint Responses in Cancer Therapy (eBook, PDF)161,95 €
- Nuclear Signaling Pathways and Targeting Transcription in Cancer (eBook, PDF)113,95 €
- Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response (eBook, PDF)161,95 €
- Cancer Proteomics (eBook, PDF)161,95 €
- Insulin-like Growth Factors and Cancer (eBook, PDF)113,95 €
- Telomeres and Telomerase in Cancer (eBook, PDF)161,95 €
-
-
-
A practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Springer US
- Seitenzahl: 674
- Erscheinungstermin: 29. Dezember 2010
- Englisch
- ISBN-13: 9781441973580
- Artikelnr.: 37339071
- Verlag: Springer US
- Seitenzahl: 674
- Erscheinungstermin: 29. Dezember 2010
- Englisch
- ISBN-13: 9781441973580
- Artikelnr.: 37339071
- Herstellerkennzeichnung Die Herstellerinformationen sind derzeit nicht verfügbar.
Section 1: Chapter 1: Basic Biostatistics for the Clinical Trialist
Authors: Elizabeth G. Hill and Elizabeth Garrett-Mayer Chapter 2:
Fundamental Concepts in Clinical Pharmacology Authors: Daniel L. Gustafson
and Erica L. Bradshaw-Pierce Chapter 3: Bioanalytical Methods in Clinical
Drug Development Authors: Walter J. Loos, Peter de Bruijn, Alex Sparreboom
Section 2 Chapter 1: Preclinical Models for Anticancer Drug Development
Author: Edward Sausville Section 3 Chapter 1: Phase I Clinical Trials with
Anticancer Agents Authors: Stephen Leong, Justin Call, Alex Adjei, Wells
Messersmith Chapter 2: Phase II Clinical Trials with Anticancer Agents
Authors: Hui Gan, J. Jack Lee, Lillian L. Siu Chapter 3: Phase III Clinical
Trials with Anticancer Agents Authors: Wendy Parulekar and Daniel J.
Sargent Chapter 4: Pharmacokinetic Studies in Early Anticancer Drug
Development Authors: Sharyn D Baker and Alex Sparreboom Chapter 5:
Pharmacodynamic Studies in Early Phase Drug Development Authors: D. Ross
Camidge, Robert C. Doebele and Antonio Jimeno Chapter 6: Prediction of
Antitumor response Authors: Yu Shyr and Fred R. Hirsch Chapter 7: Imaging
Studies in Anticancer Drug Development Author: David Mankoff Section 4
Chapter 1: Role of the US Food and Drug Administration in Cancer Drug
Development Authors: Ann T. Farrell, Ramzi N. Dagher and Richard Pazdur
Section 5 Chapter 1: Early Clinical Trials with Cytotoxic Agents Authors:
M.J.A. de Jonge and Jaap Verweij Chapter 2: Challenges and Sucesses in
Developing Effective Anti-Angiogenic Agents Authors: Laura QM Chow and S
Gail Eckhardt Chapter 3: Targeted Therapeutics in Cancer Treatment Authors:
Colin D. Weekes and Manuel Hidalgo Chapter 4: Cancer Chemoprevention
Authors: Christopher H. Lieu, William N. William Jr., Scott M. Lippman
Chapter 5: Combined Modality Therapy in Cancer Management Authors: David
Raben and Kyle Rusthoven Chapter 6: Cancer Vaccines Author: Dan Laheru
Chapter 7: Optimizing the Development of Antibodies as Treatment for Cancer
Authors: Craig P Carden, Hendrik-Tobias Arkenau and JS de Bono Chapter 8:
Oligonucleotide Therapeutics Authors: Cy A Stein, Britta Hoehn, John Rossi
Chapter 9: Anticancer Drug Development in Pediatric Patients Authors: Lia
Gore and Margaret Macy Chapter 10: Clinical Trials in Special Populations
Authors: S. Percy Ivy, MD; Merrill J. Egorin, MD; Chris H. Takimoto, MD,
PhD; and Jeannette Y. Wick, RPh Section 6: Chapter 1. NCI Sponsored
Clinical Trials Author: Janet E. Dancey and Andriana Papaconstantinou
Authors: Elizabeth G. Hill and Elizabeth Garrett-Mayer Chapter 2:
Fundamental Concepts in Clinical Pharmacology Authors: Daniel L. Gustafson
and Erica L. Bradshaw-Pierce Chapter 3: Bioanalytical Methods in Clinical
Drug Development Authors: Walter J. Loos, Peter de Bruijn, Alex Sparreboom
Section 2 Chapter 1: Preclinical Models for Anticancer Drug Development
Author: Edward Sausville Section 3 Chapter 1: Phase I Clinical Trials with
Anticancer Agents Authors: Stephen Leong, Justin Call, Alex Adjei, Wells
Messersmith Chapter 2: Phase II Clinical Trials with Anticancer Agents
Authors: Hui Gan, J. Jack Lee, Lillian L. Siu Chapter 3: Phase III Clinical
Trials with Anticancer Agents Authors: Wendy Parulekar and Daniel J.
Sargent Chapter 4: Pharmacokinetic Studies in Early Anticancer Drug
Development Authors: Sharyn D Baker and Alex Sparreboom Chapter 5:
Pharmacodynamic Studies in Early Phase Drug Development Authors: D. Ross
Camidge, Robert C. Doebele and Antonio Jimeno Chapter 6: Prediction of
Antitumor response Authors: Yu Shyr and Fred R. Hirsch Chapter 7: Imaging
Studies in Anticancer Drug Development Author: David Mankoff Section 4
Chapter 1: Role of the US Food and Drug Administration in Cancer Drug
Development Authors: Ann T. Farrell, Ramzi N. Dagher and Richard Pazdur
Section 5 Chapter 1: Early Clinical Trials with Cytotoxic Agents Authors:
M.J.A. de Jonge and Jaap Verweij Chapter 2: Challenges and Sucesses in
Developing Effective Anti-Angiogenic Agents Authors: Laura QM Chow and S
Gail Eckhardt Chapter 3: Targeted Therapeutics in Cancer Treatment Authors:
Colin D. Weekes and Manuel Hidalgo Chapter 4: Cancer Chemoprevention
Authors: Christopher H. Lieu, William N. William Jr., Scott M. Lippman
Chapter 5: Combined Modality Therapy in Cancer Management Authors: David
Raben and Kyle Rusthoven Chapter 6: Cancer Vaccines Author: Dan Laheru
Chapter 7: Optimizing the Development of Antibodies as Treatment for Cancer
Authors: Craig P Carden, Hendrik-Tobias Arkenau and JS de Bono Chapter 8:
Oligonucleotide Therapeutics Authors: Cy A Stein, Britta Hoehn, John Rossi
Chapter 9: Anticancer Drug Development in Pediatric Patients Authors: Lia
Gore and Margaret Macy Chapter 10: Clinical Trials in Special Populations
Authors: S. Percy Ivy, MD; Merrill J. Egorin, MD; Chris H. Takimoto, MD,
PhD; and Jeannette Y. Wick, RPh Section 6: Chapter 1. NCI Sponsored
Clinical Trials Author: Janet E. Dancey and Andriana Papaconstantinou
Section 1: Chapter 1: Basic Biostatistics for the Clinical Trialist
Authors: Elizabeth G. Hill and Elizabeth Garrett-Mayer Chapter 2:
Fundamental Concepts in Clinical Pharmacology Authors: Daniel L. Gustafson
and Erica L. Bradshaw-Pierce Chapter 3: Bioanalytical Methods in Clinical
Drug Development Authors: Walter J. Loos, Peter de Bruijn, Alex Sparreboom
Section 2 Chapter 1: Preclinical Models for Anticancer Drug Development
Author: Edward Sausville Section 3 Chapter 1: Phase I Clinical Trials with
Anticancer Agents Authors: Stephen Leong, Justin Call, Alex Adjei, Wells
Messersmith Chapter 2: Phase II Clinical Trials with Anticancer Agents
Authors: Hui Gan, J. Jack Lee, Lillian L. Siu Chapter 3: Phase III Clinical
Trials with Anticancer Agents Authors: Wendy Parulekar and Daniel J.
Sargent Chapter 4: Pharmacokinetic Studies in Early Anticancer Drug
Development Authors: Sharyn D Baker and Alex Sparreboom Chapter 5:
Pharmacodynamic Studies in Early Phase Drug Development Authors: D. Ross
Camidge, Robert C. Doebele and Antonio Jimeno Chapter 6: Prediction of
Antitumor response Authors: Yu Shyr and Fred R. Hirsch Chapter 7: Imaging
Studies in Anticancer Drug Development Author: David Mankoff Section 4
Chapter 1: Role of the US Food and Drug Administration in Cancer Drug
Development Authors: Ann T. Farrell, Ramzi N. Dagher and Richard Pazdur
Section 5 Chapter 1: Early Clinical Trials with Cytotoxic Agents Authors:
M.J.A. de Jonge and Jaap Verweij Chapter 2: Challenges and Sucesses in
Developing Effective Anti-Angiogenic Agents Authors: Laura QM Chow and S
Gail Eckhardt Chapter 3: Targeted Therapeutics in Cancer Treatment Authors:
Colin D. Weekes and Manuel Hidalgo Chapter 4: Cancer Chemoprevention
Authors: Christopher H. Lieu, William N. William Jr., Scott M. Lippman
Chapter 5: Combined Modality Therapy in Cancer Management Authors: David
Raben and Kyle Rusthoven Chapter 6: Cancer Vaccines Author: Dan Laheru
Chapter 7: Optimizing the Development of Antibodies as Treatment for Cancer
Authors: Craig P Carden, Hendrik-Tobias Arkenau and JS de Bono Chapter 8:
Oligonucleotide Therapeutics Authors: Cy A Stein, Britta Hoehn, John Rossi
Chapter 9: Anticancer Drug Development in Pediatric Patients Authors: Lia
Gore and Margaret Macy Chapter 10: Clinical Trials in Special Populations
Authors: S. Percy Ivy, MD; Merrill J. Egorin, MD; Chris H. Takimoto, MD,
PhD; and Jeannette Y. Wick, RPh Section 6: Chapter 1. NCI Sponsored
Clinical Trials Author: Janet E. Dancey and Andriana Papaconstantinou
Authors: Elizabeth G. Hill and Elizabeth Garrett-Mayer Chapter 2:
Fundamental Concepts in Clinical Pharmacology Authors: Daniel L. Gustafson
and Erica L. Bradshaw-Pierce Chapter 3: Bioanalytical Methods in Clinical
Drug Development Authors: Walter J. Loos, Peter de Bruijn, Alex Sparreboom
Section 2 Chapter 1: Preclinical Models for Anticancer Drug Development
Author: Edward Sausville Section 3 Chapter 1: Phase I Clinical Trials with
Anticancer Agents Authors: Stephen Leong, Justin Call, Alex Adjei, Wells
Messersmith Chapter 2: Phase II Clinical Trials with Anticancer Agents
Authors: Hui Gan, J. Jack Lee, Lillian L. Siu Chapter 3: Phase III Clinical
Trials with Anticancer Agents Authors: Wendy Parulekar and Daniel J.
Sargent Chapter 4: Pharmacokinetic Studies in Early Anticancer Drug
Development Authors: Sharyn D Baker and Alex Sparreboom Chapter 5:
Pharmacodynamic Studies in Early Phase Drug Development Authors: D. Ross
Camidge, Robert C. Doebele and Antonio Jimeno Chapter 6: Prediction of
Antitumor response Authors: Yu Shyr and Fred R. Hirsch Chapter 7: Imaging
Studies in Anticancer Drug Development Author: David Mankoff Section 4
Chapter 1: Role of the US Food and Drug Administration in Cancer Drug
Development Authors: Ann T. Farrell, Ramzi N. Dagher and Richard Pazdur
Section 5 Chapter 1: Early Clinical Trials with Cytotoxic Agents Authors:
M.J.A. de Jonge and Jaap Verweij Chapter 2: Challenges and Sucesses in
Developing Effective Anti-Angiogenic Agents Authors: Laura QM Chow and S
Gail Eckhardt Chapter 3: Targeted Therapeutics in Cancer Treatment Authors:
Colin D. Weekes and Manuel Hidalgo Chapter 4: Cancer Chemoprevention
Authors: Christopher H. Lieu, William N. William Jr., Scott M. Lippman
Chapter 5: Combined Modality Therapy in Cancer Management Authors: David
Raben and Kyle Rusthoven Chapter 6: Cancer Vaccines Author: Dan Laheru
Chapter 7: Optimizing the Development of Antibodies as Treatment for Cancer
Authors: Craig P Carden, Hendrik-Tobias Arkenau and JS de Bono Chapter 8:
Oligonucleotide Therapeutics Authors: Cy A Stein, Britta Hoehn, John Rossi
Chapter 9: Anticancer Drug Development in Pediatric Patients Authors: Lia
Gore and Margaret Macy Chapter 10: Clinical Trials in Special Populations
Authors: S. Percy Ivy, MD; Merrill J. Egorin, MD; Chris H. Takimoto, MD,
PhD; and Jeannette Y. Wick, RPh Section 6: Chapter 1. NCI Sponsored
Clinical Trials Author: Janet E. Dancey and Andriana Papaconstantinou